Cite
HARVARD Citation
Loibl, S. et al. (2018). Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet oncology. 19 (4), pp. 497-509. [Online].